All treatments
Treatment
Iclusig 15 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
This study looks at people with a type of blood cancer called CML who are doing well on a drug called Iclusig. It aims to see if they can safely stop Iclusig after taking it again, and how long they stay well without treatment.
For: Chronic myelogenous leukemiaSpain - Ongoing, recruitingTherapeutic exploratory (Phase II)
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia
This study looks at whether a medicine called Iclusig (ponatinib) can help people with a type of blood cancer called chronic myeloid leukaemia (CML) reach a point where no disease can be found, possibly leading to stopping treatment. It will check how well it works and if it's safe.
For: chronic myeloid leukemia in chronic phaseGermany